<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005598.pub4" GROUP_ID="CF" ID="503305021509501267" MERGED_FROM="" MODIFIED="2016-11-10 14:35:31 +0000" MODIFIED_BY="Tracey Remmington" REVIEW_NO="0071" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2016-11-09 11:22:36 +0000" MODIFIED_BY="Tracey Remmington">
<TITLE MODIFIED="2016-09-23 11:55:08 +0100" MODIFIED_BY="Tracey Remmington">Antibiotics for treating community-acquired pneumonia in people with sickle cell disease</TITLE>
<CONTACT>
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-11-09 11:19:38 +0000" MODIFIED_BY="Tracey Remmington">
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15042" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Lucieni</FIRST_NAME>
<MIDDLE_INITIALS>O</MIDDLE_INITIALS>
<LAST_NAME>Conterno</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinator of Infectious Diseases Discipline and Clinical Epidemiology Unit</POSITION>
<EMAIL_1>lucieni@famema.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+55 14 81216011</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of General Internal Medicine and Clinical Epidemiology Unit</DEPARTMENT>
<ORGANISATION>Marilia Medical School</ORGANISATION>
<ADDRESS_1>Avenida Monte Carmelo 800</ADDRESS_1>
<ADDRESS_2>Fragata</ADDRESS_2>
<CITY>Marilia</CITY>
<ZIP>17519-030</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 14 34021831</PHONE_1>
<PHONE_2>+55 14 34021750</PHONE_2>
<FAX_1>+55 14 34335036</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-10-20 14:16:38 +0100" MODIFIED_BY="Tracey Remmington">
<UP_TO_DATE>
<DATE DAY="23" MONTH="9" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="9" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="10" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-11-09 11:22:36 +0000" MODIFIED_BY="Tracey Remmington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-11-09 11:22:30 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="9" MONTH="11" YEAR="2016"/>
<DESCRIPTION>
<P>A search of the Cochrane Cystic Fibrosis Haemoglobinopathies Trials Register identified one potentially eligible trial, which was discarded as not relevant. The search of the LILACS database identified 19 references, which were also not relevant to the review. No other potentially relevant trials were identified by the remaining searches.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-11-09 11:22:36 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="9" MONTH="11" YEAR="2016"/>
<DESCRIPTION>
<P>The 'Plain language summary' has been re-formatted. Further minor changes were made throughout the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-09-23 11:42:57 +0100" MODIFIED_BY="Tracey Remmington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-09-23 11:42:55 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="24" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-09-23 11:42:57 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="21" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>There are no trials included in the review up to May 2012. We do not plan to update this review until new trials are published, although we will search the Group's Haemoglobinopathies Fibrosis Trials Register on a two-yearly cycle.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-09-21 14:39:33 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="6" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Minor changes have been made throughout the review.</P>
<P>The plain language summary has been amended. Some minor and major structural and textual changes to the review have been made throughout:</P>
<OL>
<LI>number of days to become afebrile is now considered as a primary outcome;</LI>
<LI>assessment risk of bias has been update (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>);</LI>
<LI>a summary of finding section has been included for the future update.</LI>
<LI>a glossary of medical terms relating to SCD has been added (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
</OL>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-21 14:39:31 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="24" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>A search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Regsiter and additional searching activities did not identify any potentially relevant trials for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-03-25 12:42:21 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>A search of the Group's Trials Register did not identify any references potentially eligible for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-17 11:29:16 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="5" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-05 16:13:25 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="1" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>None of the trials identified by the searches in 2007 were eligible for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-10-20 14:27:48 +0100" MODIFIED_BY="Tracey Remmington">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-10-20 14:27:48 +0100" MODIFIED_BY="Tracey Remmington">
<SOURCE MODIFIED="2009-03-23 20:19:07 +0000" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Network</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-10-20 14:27:34 +0100" MODIFIED_BY="Tracey Remmington">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-11-09 11:32:58 +0000" MODIFIED_BY="Tracey Remmington">
<SUMMARY MODIFIED="2016-11-09 11:27:22 +0000" MODIFIED_BY="Tracey Remmington">
<TITLE MODIFIED="2009-03-19 18:04:13 +0000" MODIFIED_BY="[Empty name]">Antibiotics for treating pneumonia caught outside of hospital or care homes in people with sickle cell disease</TITLE>
<SUMMARY_BODY MODIFIED="2016-11-09 11:27:22 +0000" MODIFIED_BY="Tracey Remmington">
<P>Tracey: See below - I have put into the newer format - please amend as necessary</P>
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence on the effect and safety of the antibiotic treatment approaches (one drug alone or combined drugs) for people with sickle cell disease with from community-acquired pneumonia. This is an update of a previously published Cochrane Review.</P>
<P>
<B>Background</B>
</P>
<P>Sickle cell disease affects millions of people throughout the world. These people can catch pneumonia more easily due to sickle damage to the spleen. The germs causing pneumonia caught in the community vary across the world. They have different sensitivities and resistance levels which are affected by how antibiotics are prescribed in that area.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to: 01 September 2016.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We were not able to find any trials to include in this review.</P>
<P>
<B>Key results</B>
</P>
<P>Trials addressing this issue should be structured and reported according to the CONSORT statement for improving the quality of reporting of efficacy and improved reports of harms in clinical research. Trial investigators should consider including the following outcomes in new trials: number of days to be free of fever, death, onset of pain crisis or complications of sickle cell disease following community-acquired pneumonia, diagnosis, hospitalization (admission rate and length of hospital stay), respiratory failure rate, and number of participants receiving a blood transfusion. Since no trials have been included in the review up until September 2016, we will still search for trials every two years, but will not publish an updated version of this review until any eligible trials are identified.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-11-09 11:23:27 +0000" MODIFIED_BY="Tracey Remmington">
<ABS_BACKGROUND MODIFIED="2016-10-20 15:22:05 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>As a consequence of their condition, people with sickle cell disease are at high risk of developing an acute infection of the pulmonary parenchyma called community-acquired pneumonia. Many different bacteria can cause this infection and antibiotic treatment is generally needed to resolve it. There is no standardized approach to antibiotic therapy and treatment is likely to vary from country to country. Thus, there is a need to identify the efficacy and safety of different antibiotic treatment approaches for people with sickle cell disease suffering from community-acquired pneumonia. This is an update of a previously published Cochrane Review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy and safety of the antibiotic treatment approaches (monotherapy or combined) for people with sickle cell disease suffering from community-acquired pneumonia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-11-09 11:23:27 +0000" MODIFIED_BY="Tracey Remmington">
<P>We searched The Group's Haemoglobinopathies Trials Register (01 September 2016), which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched LILACS (1982 to 01 September 2016), African Index Medicus (1982 to 20 October 2016) and WHO ICT Registry (20 October 2016).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We searched for published or unpublished randomized controlled trials.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-10-20 15:21:58 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We intended to summarise data by standard Cochrane methodologies, but no eligible randomized controlled trials were identified.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-09-23 12:06:15 +0100" MODIFIED_BY="Tracey Remmington">
<P>We were unable to find any randomized controlled trials on antibiotic treatment approaches for community-acquired pneumonia in people with sickle cell disease.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-10-20 15:22:17 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>The updated review was unable to identify randomized controlled trials on efficacy and safety of the antibiotic treatment approaches for people with sickle cell disease suffering from community-acquired pneumonia. Randomized controlled trials are needed to establish the optimum antibiotic treatment for this condition. The trials regarding this issue should be structured and reported according to the CONSORT statement for improving the quality of reporting of efficacy and improved reports of harms in clinical research. Triallists should consider including the following outcomes in new trials: number of days to become afebrile; mortality; onset of pain crisis or complications of sickle cell disease following community-acquired pneumonia; diagnosis; hospitalization (admission rate and length of hospital stay); respiratory failure rate; and number of participants receiving a blood transfusion.</P>
<P>There are no trials included in the review and we have not identified any relevant trials up to September 2016. We therefore do not plan to update this review until new trials are published.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-11-09 11:32:58 +0000" MODIFIED_BY="Tracey Remmington">
<BACKGROUND MODIFIED="2016-11-09 11:30:55 +0000" MODIFIED_BY="Tracey Remmington">
<P>See glossary for definitions of medical terms (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<CONDITION MODIFIED="2016-09-23 12:15:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>Sickle cell disease (SCD) was the first disease described at a molecular level (<LINK REF="REF-Pauling-1949" TYPE="REFERENCE">Pauling 1949</LINK>). It is a lifelong inherited disease and the most common haemoglobinopathy (<LINK REF="REF-Ballas-2010" TYPE="REFERENCE">Ballas 2010</LINK>; <LINK REF="REF-Orkin-2010" TYPE="REFERENCE">Orkin 2010</LINK>; <LINK REF="REF-Rees-2010" TYPE="REFERENCE">Rees 2010</LINK>) Recently, the history and others aspects of SCD have been reviewed (<LINK REF="REF-Mousa-2010" TYPE="REFERENCE">Mousa 2010</LINK>; <LINK REF="REF-Prabhakar-2010" TYPE="REFERENCE">Prabhakar 2010</LINK>; <LINK REF="REF-Serjeant-2010" TYPE="REFERENCE">Serjeant 2010</LINK>).</P>
<P>Sickle cell anaemia affects millions of people throughout the world, it is regarded as a public health priority by the World Health Organization (WHO) (<LINK REF="REF-Makani-2011" TYPE="REFERENCE">Makani 2011</LINK>). Globally, over 330,000 affected infants are born with haemoglobin disorders annually, of them 83% are born with sickle cell disorders (<LINK REF="REF-Modell-2008" TYPE="REFERENCE">Modell 2008</LINK>). An estimated 70% of sufferers live in Africa (<LINK REF="REF-Makani-2007" TYPE="REFERENCE">Makani 2007</LINK>). It is particularly common among people whose ancestors come from Sub-Saharan Africa, South America, Cuba, Central America, Saudi Arabia, India, and Mediterranean countries such as Turkey, Greece, and Italy (<LINK REF="REF-Makani-2011" TYPE="REFERENCE">Makani 2011</LINK>; <LINK REF="REF-Stuart-2004" TYPE="REFERENCE">Stuart 2004</LINK>; <LINK REF="REF-Weatherall-2006" TYPE="REFERENCE">Weatherall 2006</LINK>). In the United States of America, it affects around 72,000 people, most of whose ancestors come from Africa. The disease occurs in about one in every 500 African-American births and one in every 1000 to 1400 Hispanic-American births. Approximately two million Americans, or one in 12 African-Americans, carry the sickle cell allele (<LINK REF="REF-Loureiro-2005" TYPE="REFERENCE">Loureiro 2005</LINK>; <LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>). Prevalence for the sickle cell gene is as high as 25% to 30% in western Africa (<LINK REF="REF-Fleming-1989" TYPE="REFERENCE">Fleming 1989</LINK>).</P>
<P>The term SCD includes sickle cell anaemia (Hb SS), haemoglobin S combined with haemoglobin C (Hb SC), haemoglobin S associated with ß Thalassemia (Sß0 Thal and Sß+ Thal) and other less prevalent double heterozygous conditions which cause clinical disease (<LINK REF="REF-Steinberg-2009" TYPE="REFERENCE">Steinberg 2009</LINK>; <LINK REF="REF-Weatherall-2006" TYPE="REFERENCE">Weatherall 2006</LINK>). Haemoglobin S combined with normal haemoglobin (A) is known as the sickle cell trait (AS), which is generally asymptomatic and is not part of this review.</P>
<P>Although SCD is primarily a hematological defect, the changes in the blood red cells lead to vasculopathy associated with progressive multiorgan damage (<LINK REF="REF-Hebbel-2004" TYPE="REFERENCE">Hebbel 2004</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). The spleen and lung are two of the target organs in this population. People with SS will develop functional asplenia (hypoactivity and finally atrophy of the spleen; splenic hypofunction) (<LINK REF="REF-Begue-2001" TYPE="REFERENCE">Begue 2001</LINK>; <LINK REF="REF-Lane-1995" TYPE="REFERENCE">Lane 1995</LINK>; <LINK REF="REF-Zago-1983" TYPE="REFERENCE">Zago 1983</LINK>); this leads to frequent and often severe infections which are produced by encapsulated bacteria (<I>Streptococcus pneumoniae</I>, <I>Haemophilus influenzae</I>, <I>Mycoplasma pneumoniae</I>, <I>Chlamydia pneumoniae</I>) (<LINK REF="REF-Beytout-2003" TYPE="REFERENCE">Beytout 2003</LINK>; <LINK REF="REF-Castagnola-2003" TYPE="REFERENCE">Castagnola 2003</LINK>; <LINK REF="REF-Melles-2004" TYPE="REFERENCE">Melles 2004</LINK>; <LINK REF="REF-Vichinsky-2000" TYPE="REFERENCE">Vichinsky 2000</LINK>; <LINK REF="REF-Waghorn-2001" TYPE="REFERENCE">Waghorn 2001</LINK>). The physiopathology of the immune impairment due to hyposplenia is multifactorial (<LINK REF="REF-Chanet-2004" TYPE="REFERENCE">Chanet 2004</LINK>); immunoglobulin M (IgM) memory B cells that are responsible for the protection against infections by encapsulated bacteria, require the spleen for their generation and survival (<LINK REF="REF-Di-Sabatino-2005" TYPE="REFERENCE">Di Sabatino 2005</LINK>).</P>
<P>The two major forms of clinical lung involvement in SCD are acute chest syndrome (ACS) and sickle cell chronic lung disease (pulmonary fibrosis, pulmonary hypertension and cor pulmonale) (<LINK REF="REF-Maitre-2011" TYPE="REFERENCE">Maitre 2011</LINK>;<LINK REF="REF-Vij-2010" TYPE="REFERENCE">Vij 2010</LINK>). Both of these are associated with significant morbidity and mortality (<LINK REF="REF-Castro-2005" TYPE="REFERENCE">Castro 2005</LINK>; <LINK REF="REF-Knight-1999" TYPE="REFERENCE">Knight 1999</LINK>; <LINK REF="REF-Machado-2005" TYPE="REFERENCE">Machado 2005</LINK>; <LINK REF="REF-Siddiqui-2003" TYPE="REFERENCE">Siddiqui 2003</LINK>). Acute chest syndrome in SCD is defined by the triad of hypoxaemia, lung infiltrates on X-ray and systemic upset (<LINK REF="REF-Castro-1994" TYPE="REFERENCE">Castro 1994</LINK>; <LINK REF="REF-Golden-1998" TYPE="REFERENCE">Golden 1998</LINK>; <LINK REF="REF-Siddiqui-2003" TYPE="REFERENCE">Siddiqui 2003</LINK>; <LINK REF="REF-Stuart-2001" TYPE="REFERENCE">Stuart 2001</LINK>; <LINK REF="REF-Vichinsky-2000" TYPE="REFERENCE">Vichinsky 2000</LINK>). There are a variety of causes including infection, plate atelectasis resulting from lung splinting, vaso-occlusion and thromboembolism. Infections, such as pneumonia, can worsen SCD because local or systemic hypoxia increases sickle haemoglobin (Hb S) polymerisation (<LINK REF="REF-NIH-2002" TYPE="REFERENCE">NIH 2002</LINK>).</P>
<P>People with SCD have a susceptibility to pneumonia (<LINK REF="REF-Battersby-2010" TYPE="REFERENCE">Battersby 2010</LINK>) as a consequence of sickle damage to the spleen (<LINK REF="REF-Waterer-2005" TYPE="REFERENCE">Waterer 2005</LINK>), and are at high risk of developing an acute infection with with encapsulated bacteria that can involve the pulmonary parenchyma (proven by growth from blood or sputum and antibody levels). This is called community-acquired pneumonia (CAP), when associated with at least some symptoms of acute infection and accompanied by the presence of an acute infiltrate on a chest radiograph or auscultatory findings consistent with pneumonia (such as altered breath sounds or localized rales or both) in an individual not hospitalised or residing in a long-term care facility for more than 14 days before onset of symptoms (<LINK REF="REF-Begue-2001" TYPE="REFERENCE">Begue 2001</LINK>; <LINK REF="REF-WHO-2004" TYPE="REFERENCE">WHO 2004</LINK>). Platelet-activating factor receptor regulation is associated with an increased risk of invasive pneumococcal disease in people with SCD (<LINK REF="REF-Miller-2007" TYPE="REFERENCE">Miller 2007</LINK>).</P>
<P>People with SCD can get infections with any respiratory pathogen. In those with concomitant lung disease as a consequence of SCD, other infections may have a greater impact, especially influenza, where the inflammation that results from acute infection may exacerbate that which is pre-existing and further complicate the disease (<LINK REF="REF-Dean-2003" TYPE="REFERENCE">Dean 2003</LINK>; <LINK REF="REF-Neumayr-2003" TYPE="REFERENCE">Neumayr 2003</LINK>; <LINK REF="REF-Vichinsky-1997" TYPE="REFERENCE">Vichinsky 1997</LINK>; <LINK REF="REF-Vichinsky-2000" TYPE="REFERENCE">Vichinsky 2000</LINK>).</P>
<P>In the USA, <I>Chlamydia pneumoniae</I>, and <I>Mycoplasma pneumoniae</I> are more common as infectious agents of CAP (<LINK REF="REF-Dean-2003" TYPE="REFERENCE">Dean 2003</LINK>; <LINK REF="REF-Haas-2005" TYPE="REFERENCE">Haas 2005</LINK>; <LINK REF="REF-Neumayr-2003" TYPE="REFERENCE">Neumayr 2003</LINK>; <LINK REF="REF-Vichinsky-2000" TYPE="REFERENCE">Vichinsky 2000</LINK>). In people with SCD aged 10 years and older other causes of bacteraemia include <I>Staphylococcus aureus</I>, salmonella, enterobacter, <I>Hemophilus influenza</I>, and clostridia (<LINK REF="REF-Vichinsky-1997" TYPE="REFERENCE">Vichinsky 1997</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-09-23 11:54:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>Based on the above, antibiotic therapy (monotherapy or in combination) in people with SCD suffering from CAP is not standardized worldwide. The fact that different bacteria necessitate the use of different antibiotics leads to non-standardized therapy, although different prescribing practices, drug availability, pathogen frequency and drug resistance in different countries may also be responsible. Ceftriaxone is one of the many antibiotics used for treating this clinical condition in people with SCD and this drug is associated with autoimmune haemolytic anaemia (<LINK REF="REF-Kakaiya-2004" TYPE="REFERENCE">Kakaiya 2004</LINK>). In one observational study including people with SCD treated with ceftriaxone in an emergency department, it was reported that ceftriaxone use may not be justified (<LINK REF="REF-Jain-2002" TYPE="REFERENCE">Jain 2002</LINK>). While prophylaxis with daily oral penicillin is effective in reducing both the rate of infection and the mortality related to pneumococcal infection (<LINK REF="REF-Davies-2004" TYPE="REFERENCE">Davies 2004</LINK>; <LINK REF="REF-Gaston-1986" TYPE="REFERENCE">Gaston 1986</LINK>), this is not the sole cause of CAP. Furthermore, compliance with oral penicillin is unfortunately not always optimal and this may contribute to rising incidence of penicillin-resistant pneumococci in the community (<LINK REF="REF-Arason-1996" TYPE="REFERENCE">Arason 1996</LINK>). Despite the use of penicillin prophylaxis and pneumococcal polysaccharide vaccines, rates of invasive pneumococcal infection have continued to be observed (three out of 100) in some groups of children with SCD (<LINK REF="REF-Overturf-1999" TYPE="REFERENCE">Overturf 1999</LINK>; <LINK REF="REF-Overturf-2000" TYPE="REFERENCE">Overturf 2000</LINK>). In a systematic review of non-randomised evidence that included cases with and controls without invasive bacterial disease, the odds of SCD was 19-times greater among cases than controls (<LINK REF="REF-Ramakrishnan-2010" TYPE="REFERENCE">Ramakrishnan 2010</LINK>). For disease caused by <I>Streptococcus pneumoniae</I>, the odds of SCD was 36-times greater (<LINK REF="REF-Ramakrishnan-2010" TYPE="REFERENCE">Ramakrishnan 2010</LINK>); and for <I>Haemophilus influenzae</I> type b disease it was 13-times greater (<LINK REF="REF-Ramakrishnan-2010" TYPE="REFERENCE">Ramakrishnan 2010</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-09-06 12:45:31 +0100" MODIFIED_BY="[Empty name]">
<P>&#946;-lactam antibiotics (penicillins, amino-penicillins, cephalosporins) are the drugs for treating CAP in people with SCD, and they inhibit the synthesis of the bacterial peptidoglycan cell wall (<LINK REF="REF-Petri-2001" TYPE="REFERENCE">Petri 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-11-09 11:30:55 +0000" MODIFIED_BY="Tracey Remmington">
<P>This review aims to address the question: which antibiotics (monotherapy or in combination) are most effective for treating people with SCD suffering from CAP?</P>
<P>This is an update of a previously published Cochrane Review (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2006" TYPE="REFERENCE">Martí-Carvajal 2006</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2012" TYPE="REFERENCE">Martí-Carvajal 2012</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-09-23 12:15:42 +0100" MODIFIED_BY="Tracey Remmington">
<P>To determine the clinical effectiveness and safety of the antibiotic treatment approaches (monotherapy or combined) for people with sickle cell disease suffering from CAP.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-11-09 11:32:58 +0000" MODIFIED_BY="Tracey Remmington">
<SELECTION_CRITERIA MODIFIED="2016-09-23 12:15:58 +0100" MODIFIED_BY="Tracey Remmington">
<CRIT_STUDIES MODIFIED="2016-09-23 12:15:52 +0100" MODIFIED_BY="Tracey Remmington">
<P>Randomized controlled trials comparing different antibiotic regimens for CAP in people with SCD, irrespective of publication status (trials may be unpublished or published as an article, an abstract, or a letter), language (no language limitations will be applied) or country.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-09-23 12:15:58 +0100" MODIFIED_BY="Tracey Remmington">
<P>People with SCD, at any age, with CAP both outpatients (ambulatory) or inpatients (hospitalised), and based in any country.</P>
<P>CAP was defined as an acute infection with a proven infectious agent (from blood, sputum, or by rising antibody levels) of the pulmonary parenchyma that is associated with at least some symptoms of acute infection, accompanied by the presence of an acute infiltrate on a chest radiograph or auscultatory findings consistent with pneumonia (such as altered breath sounds or localized rales or both), in an individual not hospitalized or residing in a long-term care facility for more than 14 days before onset of symptoms (<LINK REF="REF-Bartlett-2000" TYPE="REFERENCE">Bartlett 2000</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-09-06 12:55:56 +0100" MODIFIED_BY="Tracey Remmington">
<P>We planned to include comparative studies of antibiotics (monotherapy or in combination), administered parenterally or orally and compared with another antibiotic for treating CAP in people with SCD.</P>
<P>The antibiotics were planned to be classified, with some modification as follows (<LINK REF="REF-Selim-2010" TYPE="REFERENCE">Selim 2010</LINK>):</P>
<OL>
<LI>penicillins (1st, 2nd, 3rd generation: natural; penicillinase-resistant; aminopenicillins)</LI>
<LI>anti-pseudomonal penicillins (4th generation)</LI>
<LI>cephalosporins (1st and 2nd generation)</LI>
<LI>cephalosporins (3rd and 4th generation)</LI>
<LI>carbapenems</LI>
<LI>aminoglycosides</LI>
<LI>quinolones</LI>
<LI>metronidazole</LI>
<LI>clindamycin</LI>
<LI>vancomycin</LI>
<LI>macrolides</LI>
<LI>others</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-09-23 12:07:06 +0100" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<OL>
<LI>Mortality</LI>
<OL>
<LI>pneumonia-related mortality (if pneumonia was the underlying or immediate cause of death or played a major role in the cause of death) (<LINK REF="REF-Mortensen-2002" TYPE="REFERENCE">Mortensen 2002</LINK>)</LI>
<LI>pneumonia-unrelated mortality</LI>
</OL>
</OL>
<P>2. Number of days to become afebrile*</P>
<P>*This has been re-classified from a secondary outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<OL>
<LI>Onset of pain crisis or complications of SCD following CAP diagnosis</LI>
<LI>Hospitalization</LI>
<OL>
<LI>admission rate</LI>
<LI>length of hospital stay</LI>
</OL>
<LI>Respiratory failure rate</LI>
<LI>Number of participants receiving a blood transfusion</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>We defined serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>) as any event that leads to death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, and any important medical event, which might have jeopardised the individual or requires intervention to prevent it. All other adverse events are considered non-serious.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-11-09 11:24:34 +0000" MODIFIED_BY="Tracey Remmington">
<ELECTRONIC_SEARCHES MODIFIED="2016-11-09 11:24:34 +0000" MODIFIED_BY="Tracey Remmington">
<P>Relevant trials were identified from the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms: sickle cell AND (community acquired pneumonia OR low tract infection- ti/abstr) also sickle cell AND pneumococcal.</P>
<P>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE. Unpublished work is identified by searching through the abstract books of four major conferences: the European Haematology Association conference; the American Society of Hematology conference; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of most recent search: 01 September 2016.</P>
<P>We searched the following for relevant trials (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<UL>
<LI>LILACS (1982 to 01 September 2016)</LI>
<LI>African Index Medicus (<A HREF="http://apps.who.int/trialsearch/AdvSearch.aspx">http://apps.who.int/trialsearch/AdvSearch.aspx</A>) (1982 to 20 October 2016)</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-10-20 16:21:05 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>We searched the <A HREF="http://apps.who.int/trialsearch/Default.aspx">World Health Organization International Clinical Trials</A> (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). Date of last search: 20 October 2016.</P>
<P>We searched the <A HREF="https://clinicaltrials.gov">ClinicalTrials.gov</A> (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). Date of last search: 20 October 2016.</P>
<P>The bibliographic references of all retrieved literature were reviewed for additional reports of trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-11-09 11:32:58 +0000" MODIFIED_BY="Tracey Remmington">
<P>We were unable to identify any randomized controlled trials eligible for inclusion in this review. Therefore, we could not perform the data analyses that we had planned. If trials are identified and included in the review in future, we will adhere to the protocol described below.</P>
<STUDY_SELECTION MODIFIED="2012-07-20 14:01:40 +0100" MODIFIED_BY="[Empty name]">
<P>Each review author (Arturo Martí-Carvajal (AMC) and Lucieni Oliveira Conterno (LOC)) will independently assess each reference identified by the searches to see if they met the inclusion criteria. If disagreement arises on the suitability of a trial for inclusion in the review, we plan to reach a consensus by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-07-20 14:01:50 +0100" MODIFIED_BY="[Empty name]">
<P>Each review author (AMC, LOC) will independently extract the data from included trials. If disagreement arises on the assessment of trial quality, we plan to reach a consensus by discussion.</P>
<P>We will use the statistical package RevMan 5.1 provided by the Cochrane Collaboration (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-11-09 11:25:20 +0000" MODIFIED_BY="Tracey Remmington">
<P>Each review author (AMC, LOC) will independently assess the quality of each trial using a simple form and will follow the domain-based evaluation as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions 5.1</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We will compare the assessments and discuss any discrepancies between the authors.</P>
<P>We will assess the following domains as low risk of bias, unclear or high risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<OL>
<LI>Generation of allocation sequence</LI>
<LI>Allocation concealment</LI>
<LI>Blinding (of participants, personnel and outcome assessors)</LI>
<LI>Incomplete outcome data</LI>
<LI>Selective reporting</LI>
<LI>Other sources</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">1. Generation of allocation sequence (checking for possible selection bias)</HEADING>
<P>We will describe, for each included study, the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. We will assess the method as:</P>
<UL>
<LI>low risk (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear, if the trial was described as randomized, but the method used for the allocation sequence generation was not described. </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Allocation concealment (checking for possible selection bias)</HEADING>
<P>We will describe for each included study the method used to conceal the allocation sequence in sufficient detail and determine whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We will assess the methods as:</P>
<UL>
<LI>low risk (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear, if the trial was described as randomized, but the method used to conceal the allocation was not described.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Blinding or masking (checking for possible performance bias)</HEADING>
<P>We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We will judge studies at low risk of bias if they were blinded, or if we will judge that the lack of blinding could not have affected the results. We will assess blinding separately for different outcomes or classes of outcomes. We will assess the methods as:</P>
<UL>
<LI>low risk, high risk or unclear for participants;</LI>
<LI>low risk, high risk or unclear for personnel;</LI>
<LI>low risk, high risk or unclear for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We will assess assess the studies in the following way.<BR/>
</P>
<UL>
<LI>Low risk (any one of the following): no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</LI>
<LI>High risk (any one of the following): reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;As-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomization; potentially inappropriate application of simple imputation.</LI>
<LI>Unclear risk (any one of the following): insufficient reporting of attrition/exclusions to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217; (e.g. number randomized not stated, no reasons for missing data provided); the study did not address this outcome.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Selective reporting bias (reporting bias due to selective outcome reporting)</HEADING>
<P>We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found. We will assess the methods in the following way.</P>
<UL>
<LI>Low risk (any one of the following): the study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way or the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</LI>
<LI>High risk (any one of the following): not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. sub scales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</LI>
<LI>Unclear: insufficient information to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Free of other bias (bias due to problems not covered elsewhere in the table)</HEADING>
<P>We will describe for each included study any important concerns we have about other possible sources of bias (baseline imbalance, sponsorship bias, confirmation bias, bias of the presentation data, etc).</P>
<UL>
<LI>Low risk of bias: the trial appears to be free of other components that could put it at risk of bias.</LI>
<LI>Unclear risk of bias: the trial may or may not be free of other components that could put it at risk of bias.</LI>
<LI>High risk of bias: there are other factors in the trial that could put it at risk of bias, e.g. no sample size calculation made.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Overall risk of bias</HEADING>
<P>We will make explicit judgements about whether studies are at high risk of bias, according to the criteria given in the <I>Cochrane Handbook of Systematic reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to the first six domains above, we plan to assess the likely magnitude and direction of the bias and whether we consider it is likely to impact on the findings. Trials assessed as having 'low risk of bias' in all of the specified above individual domains will be considered 'trials with low risk of bias'.</P>
<P>Trials assessed as having 'unclear risk of bias' or 'high risk of bias' in one or more of the specified above individual domains will be considered trials with a 'high risk of bias'</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-09-06 12:41:18 +0100" MODIFIED_BY="[Empty name]">
<P>We plan to summarise binary outcome measures (mortality, pneumonia-unrelated mortality, onset of pain crisis or complications of SCD following CAP diagnosis, respiratory failure rate, number of participants receiving a blood transfusion, and safety) in terms of risk ratios (RR), with 95% confidence intervals (CIs), by extracting numbers in each group.<BR/>
<BR/>For continuous outcomes (number of participants receiving a blood transfusion) we plan to record either mean change from baseline for each group or mean post-treatment or intervention values and their standard deviation (SD) or standard error (SE) for each group. We also plan to calculate a pooled estimate of treatment effect by calculating the mean difference (MD) and 95% CIs. If statistics are missing (such as standard deviations), we will try to extract them from other relevant information in the paper, such as P-values and CIs. If this is not possible, the first author of the paper will be contacted.</P>
<P>For time to event outcomes (number of days to become afebrile, days of hospital stay) we plan to record the log-hazard ratio and standard errors from Cox proportional hazards models then combine study results using the generic inverse variance method. If only log-rank or a mixture of log-rank and Cox model estimates are available, the log rank estimates will first be converted into log-hazard ratios with associated standard errors.</P>
<P>We will examine data to see if there is evidence of a skewed distribution using the means and standard deviations as described in the <I>Cochrane Handbook of Systematic Reviews for Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Continuous data will be classed as being skewed if the standard deviation is over half the size of the mean (this is only true if the data can take positive values only, it does not apply to change data, for example). If data are skewed, when appropriate, we will aim to present log-transformed data. Skewed data will not be pooled, the results will be presented in additional tables, with no statistical analyses performed on these data.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2008-11-05 16:33:14 +0000" MODIFIED_BY="Tracey Remmington">
<P>Additional information will be requested from the primary authors of the included trials, when necessary.</P>
<P>In order to allow an intention-to-treat analysis, we will seek data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-05-05 20:52:01 +0100" MODIFIED_BY="[Empty name]">
<P>We will quantify statistical heterogeneity using the I<SUP>2 </SUP>statistic, which describes the percentage of total variation across trials that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We will consider there to be significant statistical heterogeneity if I<SUP>2 </SUP>is over 50% (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-03-23 20:08:01 +0000" MODIFIED_BY="[Empty name]">
<P>We will attempt to assess whether the review is subject to publication bias by using a funnel plot to graphically illustrate variability between trials. If asymmetry is detected, causes other than publication bias will be explored.</P>
<P>We will attempt to contact subject experts and any other relevant register databases in an attempt to identify unpublished papers. Our aim is to reduce the chance of outcome reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-09-06 12:45:13 +0100" MODIFIED_BY="[Empty name]">
<P>If any future identified trials are comparable , we will summarize their findings using a fixed-effect model, if not (I<SUP>2</SUP> is over 50%), we will use a random-effects model, and we will investigate the cause of the heterogeneity according the Cochrane Handbook of Systematic Reviews for Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-09-06 12:41:44 +0100" MODIFIED_BY="[Empty name]">
<P>Where heterogeneity is found, the possible causes will be investigated further. If significant heterogeneity is detected, we will investigate possible causes for heterogeneity.by conducting one or more of the following subgroup analyses:</P>
<OL>
<LI>severity of disease;</LI>
<LI>use of antibiotic covering atypical agents;</LI>
<LI>participants on ventilatory support;</LI>
<LI>participants' age;</LI>
<LI>antibiotics' routes of administration;</LI>
<LI>SS type versus SC type.</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-11-09 11:32:58 +0000" MODIFIED_BY="Tracey Remmington">
<P>If sufficient trials are identified, we plan to conduct a sensitivity analysis comparing the results using all trials and using only those of high methodological quality (studies classified as having a 'low risk of bias' versus those identified as having a 'high risk of bias') (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>We will use the principles of the GRADE system (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>) to assess the quality of the body of evidence associated with all primary and secondary outcomes (mortality, number of days to become afebrile, onset of pain crisis or complications of SCD following CAP diagnosis, respiratory failure rate, number of participants receiving a blood transfusion, adverse events) using the GRADE profiler software (<LINK REF="REF-GRADEPro-2014" TYPE="REFERENCE">GRADEPro 2014</LINK>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Evaluation of the  quality of a body of evidence considers within-study risk of bias, the directness of the evidence, heterogeneity in the data, precision of effect estimates and the risk of publication bias (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>; <LINK REF="REF-Guyatt-2011f" TYPE="REFERENCE">Guyatt 2011f</LINK>; <LINK REF="REF-Guyatt-2011g" TYPE="REFERENCE">Guyatt 2011g</LINK>; <LINK REF="REF-Guyatt-2011h" TYPE="REFERENCE">Guyatt 2011h</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-09-06 13:15:06 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-09-06 13:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>After manually checking the titles and abstracts, none of the references identified were eligible for further evaluation.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-03-23 20:13:11 +0000" MODIFIED_BY="[Empty name]">
<P>No RCTs were included.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-03-23 20:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>The search did not identify any RCTs eligible for inclusion in this systematic review, nor were we able to identify any ongoing trials.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-11-09 11:27:47 +0000" MODIFIED_BY="Tracey Remmington">
<SUMMARY_OF_RESULTS MODIFIED="2016-09-23 12:16:55 +0100" MODIFIED_BY="Tracey Remmington">
<P>We have been unable to identify any clinical trials addressing the efficacy or safety of antibiotic treatment approaches for treating community-acquired pneumonia (CAP) in people with sickle cell disease (SCD). This is surprising in light of the number of people worldwide who suffer from this severe complication of SCD; CAP can be an emergency in people with SCD (<LINK REF="REF-Hampton-2005" TYPE="REFERENCE">Hampton 2005</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-09-23 12:17:29 +0100" MODIFIED_BY="Tracey Remmington">
<P>This Cochrane Review did not find randomized controlled trials (RCTs) of antibiotics for treating CAP in people with SCD. Therefore, it was not possible to determine the efficacy and safety of the antibiotic treatment approaches (monotherapy or combined) for people with SCD suffering from CAP.</P>
<P>In 2002, WHO recognized a decline in child mortality due to pneumonia, but stated that it remains a very important cause of death in developing countries (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). Bacterial infections are still a major cause of morbidity and mortality among young children with SCD (<LINK REF="REF-Ashley_x002d_Koch-2000" TYPE="REFERENCE">Ashley-Koch 2000</LINK>; <LINK REF="REF-Falcao-1989" TYPE="REFERENCE">Falcao 1989</LINK>; <LINK REF="REF-Lepage-2004" TYPE="REFERENCE">Lepage 2004</LINK>; <LINK REF="REF-Pelton-2005" TYPE="REFERENCE">Pelton 2005</LINK>; <LINK REF="REF-Pimentel-2003" TYPE="REFERENCE">Pimentel 2003</LINK>). These children have an increased prevalence of single and multiple attacks of pneumonia, which run a more serious clinical course than in those people without SCD (<LINK REF="REF-De-Ceulaer-1985" TYPE="REFERENCE">De Ceulaer 1985</LINK>; <LINK REF="REF-Sandora-2005" TYPE="REFERENCE">Sandora 2005</LINK>). Several infectious agents can produce pneumonia in people with SCD (<LINK REF="REF-Landesman-1982" TYPE="REFERENCE">Landesman 1982</LINK>); even with current vaccination and prophylactic antibiotic regimens (<LINK REF="REF-Adamkiewicz-2003" TYPE="REFERENCE">Adamkiewicz 2003</LINK>; <LINK REF="REF-Bogaert-2004" TYPE="REFERENCE">Bogaert 2004</LINK>; <LINK REF="REF-Saunthararajah-2005" TYPE="REFERENCE">Saunthararajah 2005</LINK>). People with SCD are non-immunocompetent hosts (<LINK REF="REF-Begue-2001" TYPE="REFERENCE">Begue 2001</LINK>; <LINK REF="REF-Landesman-1982" TYPE="REFERENCE">Landesman 1982</LINK>; <LINK REF="REF-Plouffe-2004" TYPE="REFERENCE">Plouffe 2004</LINK>).</P>
<P>There have been "three decades of innovation in the management of sickle cell disease" to improve the quality of treatment management for people with SCD (<LINK REF="REF-Bonds-2005" TYPE="REFERENCE">Bonds 2005</LINK>), but no RCTs investigating the efficacy and safety of antibiotic treatment approaches for CAP in people with SCD have yet been conducted. This is despite the strong link between pneumonia and SCD; the high frequency of this disease; and the large number of trials needed to account for the variation in CAP bacteria and their antibiotic sensitivities or resistances due to geography and differing antibiotic prescription practice (<LINK REF="REF-Klugman-2004" TYPE="REFERENCE">Klugman 2004</LINK>; <LINK REF="REF-Metlay-2004" TYPE="REFERENCE">Metlay 2004</LINK>; <LINK REF="REF-Paradisi-2000" TYPE="REFERENCE">Paradisi 2000</LINK>; <LINK REF="REF-Pimentel-2003" TYPE="REFERENCE">Pimentel 2003</LINK>). This lack of trials shows a gap between clinical medicine and clinical investigation.</P>
<P>It is widely known that clinicians make practical decisions, often on the basis of inadequate information; this can lead to a poor response to conventional treatment in people with pneumonia (<LINK REF="REF-Tan-2004" TYPE="REFERENCE">Tan 2004</LINK>), whilst having an increased risk for developing resistant pneumococcal infections (<LINK REF="REF-File-2004" TYPE="REFERENCE">File 2004</LINK>; <LINK REF="REF-Jacobs-2004" TYPE="REFERENCE">Jacobs 2004</LINK>; <LINK REF="REF-Segreti-2005" TYPE="REFERENCE">Segreti 2005</LINK>). Decisions about treatment should be taken based on the results of randomized trials (<LINK REF="REF-Chalmers-2004" TYPE="REFERENCE">Chalmers 2004</LINK>), but as Lottenberg states "The application of evidence-based medicine to the management of adults with sickle cell disease is currently primarily driven by clinical expertise and patient preference, as there is a paucity of randomized controlled trial data to guide decision-making" (<LINK REF="REF-Lottenberg-2005" TYPE="REFERENCE">Lottenberg 2005</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-03-25 14:42:11 +0000" MODIFIED_BY="[Empty name]">
<P>RCTs were not found on this clinical entity. </P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-11-09 11:27:42 +0000" MODIFIED_BY="Tracey Remmington">
<P>The main limitation of this Cochrane Review is the paucity of evidence in people with SCD suffering from CAP. Publication bias is an important factor that affects the validity of systematic reviews and can modify the quality of the evidence. However, we did an exhaustive search which included many clinical trial registries, but we were not able to find any registered completed trials that were unpublished. Unfortunately, it was not possible to search the EMBASE database from 2008 to 2009.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-11-09 11:27:47 +0000" MODIFIED_BY="Tracey Remmington">
<P>There are no other reviews or studies to compare with this Cochrane Review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-11-09 11:27:57 +0000" MODIFIED_BY="Tracey Remmington">
<IMPLICATIONS_PRACTICE MODIFIED="2016-11-09 11:27:57 +0000" MODIFIED_BY="Tracey Remmington">
<P>No randomized controlled trials of antibiotics in people with SCD suffering from CAP were found for inclusion in this review. Therefore, it was not possible to determine the efficacy and safety of the antibiotic treatment approaches (monotherapy or combined) for people with CAP suffering from SCD. Hence, we recommend that until evidence becomes available, clinicians continue to treat individuals on a case by case basis given the diagnosis and treatments available to them.</P>
<P>There are no trials included in the review and we have not identified any relevant trials up to September 2016. We therefore do not plan to update this review until new trials are published.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-09-23 12:16:17 +0100" MODIFIED_BY="Tracey Remmington">
<P>This systematic review has identified the need for well-designed, adequately-powered randomized controlled trials to assess the benefits and harms of antibiotic treatment approaches (monotherapy or combined) as a way of improving the survival and decreasing mortality from CAP in people with SCD.</P>
<P>Due to the variability of the clinical practice for treating CAP in this population (inter-countries and intra-country), lack of definition of mild CAP in people with SCD, and the immunocompromised state of those individuals, it is not easy to recommend specific outcomes which should be included into RCTs for this clinical entity. For example, some clinical outcomes are not recommended to be included in RCTs for outpatients with mild CAP (mortality, return to &#8220;normal&#8221; activities of daily living, microbiological response, chest radiography and admission to the hospital) (<LINK REF="REF-Gilbert-2008" TYPE="REFERENCE">Gilbert 2008</LINK>). On the contrary, end points such as patient-reported outcomes and time-to-response are recommended for this clinical issue (<LINK REF="REF-Gilbert-2008" TYPE="REFERENCE">Gilbert 2008</LINK>). Infectious Diseases Society of America has recommended "Design Features of Future Clinical Trials of Antibacterial Agents for Community-Acquired Pneumonia" (<LINK REF="REF-ISDA-2008" TYPE="REFERENCE">ISDA 2008</LINK>). However, SCD was not specifically considered in that position paper. CAP has a major impact in people with SCD, more so than in people without that hereditary disease which affects the immune system.</P>
<P>The American Society of Hematology has stated "Due to the complexity of this disease, the numerous side-effects of treatments, and the potential for hospitalization, patients should be closely monitored and have access to specialized care" (<LINK REF="REF-ASH-2008" TYPE="REFERENCE">ASH 2008</LINK>). Therefore, it would be desirable, in order to improve the well-being and quality of life of that population, to conduct a workshop about this clinical condition in SCD, so that the rules for performing RCTs are defined. This workshop should include haematologists, experts in infectious diseases and methodologists in RCTs from throughout the world.</P>
<P>The trials regarding this issue should be structured and reported according to the CONSORT statement (<A HREF="http://www.consort-statement.org">www.consort-statement.org</A>) for improving the quality of reporting of efficacy and improved reports of harms in clinical research.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-11-09 11:30:13 +0000" MODIFIED_BY="Tracey Remmington">
<UL>
<LI>For this update</LI>
</UL>
<OL>
<LI>Tracey Remmenington from The Cochrane Cystic Fibrosis and Genetic Disorders Group for her help and editorial advice during preparation of this Cochrane Review.</LI>
<LI>the Iberoamerican Cochrane Centre, Spain.</LI>
</OL>
<UL>
<LI>For the previous updates and original Cochrane Review.</LI>
</UL>
<OL>
<LI>The Iberoamerican Cochrane Centre, Spain.</LI>
<LI>Tracey Remmenington from The Cochrane Cystic Fibrosis and Genetic Disorders Group for her help and editorial advice during preparation of this Cochrane Review.</LI>
<LI>The Contact Editors, Professor Dame Sally Davies and Dr Ian Hambleton for their useful comments.</LI>
<LI>Nikki Jahnke from the Cochrane Cystic Fibrosis and Genetic Disorders Group for her help and editorial advice during preparation of this Cochrane Review.</LI>
<LI>Mr Ivan Solá from Iberoamerican Cochrane Centre for his help during preparation of the protocol of this Cochrane Review.</LI>
</OL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-09-23 11:59:33 +0100" MODIFIED_BY="Tracey Remmington">
<P>All authors: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-11-09 11:30:24 +0000" MODIFIED_BY="Tracey Remmington">
<P>Arturo Martí-Carvajal drafted the protocol and the review with comments from Lucieni Conterno and has prepared the updates.</P>
<P>Arturo Martí-Carvajal acts as guarantor for the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-09-06 12:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>
<BR/>In response to the position paper for recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia (<LINK REF="REF-ISDA-2008" TYPE="REFERENCE">ISDA 2008</LINK>), a second primary outcome measure - the number of days to become afebrile - has been added. This change addresses the increasing possibility that trials conducted in many geographical locations are unlikely to have adequate power to examine the original 'all-cause mortality' endpoint. It therefore allows the inclusion of trials assessing interventions for 'mild' or 'moderate' CAP as defined in the position paper. This new primary endpoint would be assessed by 'time-to-event' analyses.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2009-03-17 12:11:06 +0000" MODIFIED_BY="Nikki Jahnke"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-11-10 14:35:31 +0000" MODIFIED_BY="Tracey Remmington">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-11-09 11:33:52 +0000" MODIFIED_BY="Tracey Remmington">
<ADDITIONAL_REFERENCES MODIFIED="2016-11-09 11:33:52 +0000" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Adamkiewicz-2003" NAME="Adamkiewicz 2003" TYPE="JOURNAL_ARTICLE">
<AU>Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH et al</AU>
<TI>Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>4</NO>
<PG>438-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arason-1996" NAME="Arason 1996" TYPE="JOURNAL_ARTICLE">
<AU>Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S</AU>
<TI>Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7054</NO>
<PG>387-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ASH-2008" MODIFIED="2009-06-15 16:41:46 +0100" MODIFIED_BY="Nikki Jahnke" NAME="ASH 2008" TYPE="OTHER">
<AU>Kaushansky K</AU>
<TI>Special Needs Plan for Chronic Conditions</TI>
<SO>http://www.hematology.org/policy/testimony/ASH_Comments_re_Special_Needs_Plan_for_Chronic_Conditions.pdf</SO>
<YR>(accessed November 1st 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ashley_x002d_Koch-2000" NAME="Ashley-Koch 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ashley-Koch A, Yang Q, Olney RS</AU>
<TI>Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2000</YR>
<VL>151</VL>
<NO>9</NO>
<PG>839-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballas-2010" MODIFIED="2011-05-12 16:49:16 +0100" MODIFIED_BY="[Empty name]" NAME="Ballas 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C et al</AU>
<TI>Definitions of the phenotypic manifestations of sickle cell disease</TI>
<SO>American Journal of Hematology</SO>
<YR>2010</YR>
<VL>85</VL>
<NO>1</NO>
<PG>6-13</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:49:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2012-04-27 17:56:12 +0100" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21208779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bartlett-2000" NAME="Bartlett 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ</AU>
<TI>Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America</TI>
<SO>Clinical Infectious Disease</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>2</NO>
<PG>347-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Battersby-2010" MODIFIED="2011-05-09 23:08:21 +0100" MODIFIED_BY="[Empty name]" NAME="Battersby 2010" TYPE="JOURNAL_ARTICLE">
<AU>Battersby AJ, Knox-Macaulay HH, Carrol ED</AU>
<TI>Susceptibility to invasive bacterial infections in children with sickle cell disease</TI>
<SO>Pediatric Blood &amp; Cancer</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>3</NO>
<PG>401-6</PG>
<IDENTIFIERS MODIFIED="2011-05-09 23:08:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Begue-2001" NAME="Begue 2001" TYPE="JOURNAL_ARTICLE">
<AU>Begue P, Castello-Herbreteau B</AU>
<TI>Severe infections in children with sickle cell disease: clinical aspects and prevention</TI>
<TO>Infections graves chez renfant l´ drèpanocytaire aspects cliniques et prèvention</TO>
<SO>Archives de Pediatrie</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>Suppl 4</NO>
<PG>732s-41s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beytout-2003" MODIFIED="2011-05-12 16:49:30 +0100" MODIFIED_BY="[Empty name]" NAME="Beytout 2003" TYPE="JOURNAL_ARTICLE">
<AU>Beytout J, Tournilhac O, Laurichesse H</AU>
<TI>Asplenia and hyposplenism</TI>
<SO>La Presse Medicale</SO>
<YR>2003</YR>
<VL>32</VL>
<NO>28 Suppl</NO>
<PG>S5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bogaert-2004" NAME="Bogaert 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bogaert D, de Groot R, Hermans PWM</AU>
<TI>Streptococcus pneumoniae colonisation: the key to pneumococcal disease</TI>
<SO>Lancet Infectious Disease</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>3</NO>
<PG>144-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonds-2005" NAME="Bonds 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bonds DR</AU>
<TI>Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype</TI>
<SO>Blood Review</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>2</NO>
<PG>99-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castagnola-2003" NAME="Castagnola 2003" TYPE="JOURNAL_ARTICLE">
<AU>Castagnola E, Fioredda F</AU>
<TI>Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes</TI>
<SO>European Journal of Haematology</SO>
<YR>2003</YR>
<VL>71</VL>
<NO>5</NO>
<PG>319-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castro-1994" NAME="Castro 1994" TYPE="JOURNAL_ARTICLE">
<AU>Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al</AU>
<TI>The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>84</VL>
<NO>2</NO>
<PG>643-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castro-2005" NAME="Castro 2005" TYPE="JOURNAL_ARTICLE">
<AU>Castro O, Gladwin MT</AU>
<TI>Pulmonary Hypertension in Sickle Cell Disease: Mechanisms, Diagnosis, and Management</TI>
<SO>Hematology/Oncology Clinics of North America</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>5</NO>
<PG>881-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-2004" NAME="Chalmers 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I</AU>
<TI>Well informed uncertainties about the effects of treatments</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7438</NO>
<PG>475-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chanet-2004" NAME="Chanet 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chanet V, Lesens O, Laurichesse H, Beytout J</AU>
<TI>Prevention and infection in adults patients with hyposplenism</TI>
<TO>Infections chez l'adulte asplénique et prévention</TO>
<SO>Medecine et maladies infectieuses</SO>
<YR>2004</YR>
<VL>34</VL>
<NO>11</NO>
<PG>493-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-2004" MODIFIED="2011-05-12 17:00:52 +0100" MODIFIED_BY="[Empty name]" NAME="Davies 2004" TYPE="COCHRANE_REVIEW">
<AU>Davies EG, Hirst C, Lottenberg R, Dower N</AU>
<TI>Pneumococcal vaccines for sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-05-12 17:00:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2011-05-12 17:00:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003885.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Ceulaer-1985" NAME="De Ceulaer 1985" TYPE="JOURNAL_ARTICLE">
<AU>De Ceulaer K, McMullen KW, Maude GH, Keatinge R, Serjeant GR</AU>
<TI>Pneumonia in young children with homozygous sickle cell disease: risk and clinical features</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1985</YR>
<VL>144</VL>
<NO>3</NO>
<PG>255-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dean-2003" NAME="Dean 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dean D, Neumayr L, Kelly DM, Ballas SK, Kleman K, Robertson S,et al</AU>
<TI>Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>1</NO>
<PG>46-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Sabatino-2005" NAME="Di Sabatino 2005" TYPE="JOURNAL_ARTICLE">
<AU>Di Sabatino A, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Corazza GR et al</AU>
<TI>Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>8</NO>
<PG>1788-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falcao-1989" NAME="Falcao 1989" TYPE="JOURNAL_ARTICLE">
<AU>Falcao RP, Donadi EA</AU>
<TI>Infection and immunity in sickle cell disease</TI>
<SO>Revista da Associacao Medica Brasileira</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>2</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-File-2004" NAME="File 2004" TYPE="JOURNAL_ARTICLE">
<AU>File TM</AU>
<TI>Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>117</VL>
<NO>Suppl 3A</NO>
<PG>39S&#8211;50S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleming-1989" NAME="Fleming 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fleming AF</AU>
<TI>The presentation, management and prevention of crisis in sickle cell disease in Africa</TI>
<SO>Blood Review</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>1</NO>
<PG>18-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaston-1986" MODIFIED="2009-05-19 14:57:59 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Gaston 1986" TYPE="JOURNAL_ARTICLE">
<AU>Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G et al</AU>
<TI>Prophylaxis with oral penicillin in children with sickle cell anemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<NO>25</NO>
<PG>1593-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-2008" MODIFIED="2009-04-15 13:02:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Gilbert 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert DN</AU>
<TI>Clinical end points of therapy for patients with mild community-acquired pneumonia</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>Suppl 3</NO>
<PG>140-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Golden-1998" NAME="Golden 1998" TYPE="JOURNAL_ARTICLE">
<AU>Golden C, Styles L, Vichinsky E</AU>
<TI>Acute chest syndrome and sickle cell disease</TI>
<SO>Current Opinion in Hematology</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>2</NO>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEPro-2014" MODIFIED="2016-11-09 11:33:52 +0000" MODIFIED_BY="Tracey Remmington" NAME="GRADEPro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>accessed 09 November 2016</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2012-05-11 10:32:18 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence--imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21839614"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2012-05-11 10:33:24 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence--inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21803546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2012-05-11 10:33:28 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence--publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21802904"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2012-05-11 10:33:32 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence--indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21802903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2012-05-11 10:33:35 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21802902"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011f" MODIFIED="2012-05-11 10:33:40 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011f" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21247734"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011g" MODIFIED="2012-05-11 10:33:45 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011g" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21195583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011h" MODIFIED="2012-05-11 10:31:38 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011h" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A</AU>
<TI>GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>380-2</PG>
<IDENTIFIERS MODIFIED="2012-04-27 17:47:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21185693"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haas-2005" NAME="Haas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Haas H</AU>
<TI>Antibiotherapy in children with atypical bacterial infections</TI>
<TO>Antibiothérapie des infections à bactéries atypiques de l'enfant</TO>
<SO>Archives de pediatrie</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>Suppl 1</NO>
<PG>S45-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hampton-2005" NAME="Hampton 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hampton R, Balasa V, Allen Bracey SE</AU>
<TI>Emergencies in patients with inherited hemoglobin disorders&#8212;An emergency department perspective</TI>
<SO>Clinical Pediatric Emergency Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>3</NO>
<PG>138-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebbel-2004" MODIFIED="2009-03-23 16:16:50 +0000" MODIFIED_BY="[Empty name]" NAME="Hebbel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hebbel RP, Osarogiagbon R, Kaul D</AU>
<TI>The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy</TI>
<SO>Microcirculation</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>129-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-05-05 20:52:22 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" NAME="ICH-GCP 1997" TYPE="OTHER">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<TI>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice</TI>
<SO>www.ich.org/cache/compo/276-254-1.html</SO>
<YR>(accessed 18th May 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISDA-2008" MODIFIED="2009-04-15 13:02:39 +0100" MODIFIED_BY="Nikki Jahnke" NAME="ISDA 2008" TYPE="JOURNAL_ARTICLE">
<AU>Infectious Diseases Society of America</AU>
<TI>Position Paper: Recommended Design Featuresof Future Clinical Trials of Antibacterial Agents for Community-Acquired Pneumonia</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>Suppl 3</NO>
<PG>249-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobs-2004" NAME="Jacobs 2004" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs MR</AU>
<TI>Streptococcus pneumoniae: epidemiology and patterns of resistance</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>117</VL>
<NO>Suppl 3A</NO>
<PG>3S-15S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jain-2002" MODIFIED="2009-03-25 18:38:35 +0000" MODIFIED_BY="[Empty name]" NAME="Jain 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jain S, Sullivan K</AU>
<TI>Ceftriaxone use in the emergency department: are we doing it right?</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2002</YR>
<VL>18</VL>
<PG>259-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kakaiya-2004" MODIFIED="2009-03-25 18:27:20 +0000" MODIFIED_BY="[Empty name]" NAME="Kakaiya 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kakaiya R, Cseri J, Smith S, Silberman S, Rubinas TC, Hoffstadter A</AU>
<TI>A case of acute hemolysis after ceftriaxone: immune complex mechanism demonstrated by flow cytometry</TI>
<SO>Archives of Pathology and Laboratory Medicine</SO>
<YR>2004</YR>
<VL>128</VL>
<PG>905-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klugman-2004" NAME="Klugman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Klugman KP, Low DE, Metlay J, Pechere JC, Weiss K</AU>
<TI>Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>5</NO>
<PG>411-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knight-1999" NAME="Knight 1999" TYPE="JOURNAL_ARTICLE">
<AU>Knight J, Murphy TM, Browning I</AU>
<TI>The lung in sickle cell disease</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>3</NO>
<PG>205-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landesman-1982" NAME="Landesman 1982" TYPE="JOURNAL_ARTICLE">
<AU>Landesman SH, Rao SP, Ahonkhai VI</AU>
<TI>Infections in children with sickle cell anemia. Special reference to pneumococcal and salmonella infections</TI>
<SO>The American Journal of Pediatric Hematology/Oncology</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>4</NO>
<PG>407-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lane-1995" NAME="Lane 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lane PA, O'Connell JL, Lear JL, Rogers ZR, Woods GM, Hassell KL et al</AU>
<TI>Functional asplenia in hemoglobin SC disease</TI>
<SO>Blood</SO>
<YR>1995</YR>
<VL>85</VL>
<NO>8</NO>
<PG>2238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lepage-2004" NAME="Lepage 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lepage P, Dresse MF, Forget P, Schmitz V, Hoyoux C</AU>
<TI>Infections and antibiotic prophylaxis in sickle cell disease</TI>
<SO>Revue Medicale de Liege</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>3</NO>
<PG>145-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lottenberg-2005" NAME="Lottenberg 2005" TYPE="BOOK_SECTION">
<AU>Lottenberg R, Hassell KL</AU>
<TI>An evidence-based approach to the treatment of adults with sickle cell disease</TI>
<SO>Hematology (Am Soc Hematol Educ Program)</SO>
<YR>2005</YR>
<PB>The American Society of Hematology</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loureiro-2005" NAME="Loureiro 2005" TYPE="JOURNAL_ARTICLE">
<AU>Loureiro MM, Rozenfeld S</AU>
<TI>Epidemiology of sickle cell disease hospital admissions in Brazil</TI>
<SO>Revista de Saúde Pública</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>6</NO>
<PG>943-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Machado-2005" NAME="Machado 2005" TYPE="JOURNAL_ARTICLE">
<AU>Machado RF, Gladwin MT</AU>
<TI>Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension</TI>
<SO>British Journal of Hematology</SO>
<YR>2005</YR>
<VL>129</VL>
<NO>4</NO>
<PG>449-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maitre-2011" MODIFIED="2011-05-09 23:35:18 +0100" MODIFIED_BY="[Empty name]" NAME="Maitre 2011" TYPE="JOURNAL_ARTICLE">
<AU>Mâitre B, Mekontso-Dessap A, Habibi A, Bachir D, Parent F, Godeau B et al</AU>
<TI>Pulmonary complications in adult sickle cell disease</TI>
<TO>Complications pulmonaires des syndromes drepanocytaires majeurs chez l'adulte.</TO>
<SO>Revue des Maladies Respiratoires</SO>
<YR>2011</YR>
<VL>28</VL>
<NO>2</NO>
<PG>129-37</PG>
<IDENTIFIERS MODIFIED="2011-05-09 23:34:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Makani-2007" MODIFIED="2011-05-12 16:33:59 +0100" MODIFIED_BY="[Empty name]" NAME="Makani 2007" TYPE="JOURNAL_ARTICLE">
<AU>Makani J, Williams TN, Marsh K</AU>
<TI>Sickle cell disease in Africa: burden and research priorities</TI>
<SO>Annals of tropical medicine and parasitology</SO>
<YR>2007</YR>
<VL>101</VL>
<NO>1</NO>
<PG>3-14</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:33:56 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="17244405"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Makani-2011" MODIFIED="2011-05-09 23:51:08 +0100" MODIFIED_BY="[Empty name]" NAME="Makani 2011" TYPE="JOURNAL_ARTICLE">
<AU>Makani J, Cox SE, Soka D, Komba AN, Oruo J, Mwamtemi H et al</AU>
<TI>Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania</TI>
<SO>PloS one</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>2</NO>
<PG>e14699</PG>
<IDENTIFIERS MODIFIED="2011-05-09 23:51:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Melles-2004" NAME="Melles 2004" TYPE="JOURNAL_ARTICLE">
<AU>Melles DC, de Marie S</AU>
<TI>Prevention of infections in hyposplenic and asplenic patients: an update</TI>
<SO>The Netherlands Journal of Medicine</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>2</NO>
<PG>45-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metlay-2004" NAME="Metlay 2004" TYPE="JOURNAL_ARTICLE">
<AU>Metlay JP</AU>
<TI>Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia</TI>
<SO>Infectious disease clinics of North America</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>4</NO>
<PG>777-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2007" MODIFIED="2009-03-20 16:31:15 +0000" MODIFIED_BY="[Empty name]" NAME="Miller 2007" TYPE="JOURNAL_ARTICLE">
<AU>Miller ML, Gao G, Pestina T, Persons D, Tuomanen E</AU>
<TI>Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor</TI>
<SO>Journal of Infectious Disease</SO>
<YR>2007</YR>
<VL>195</VL>
<PG>581-4</PG>
<IDENTIFIERS MODIFIED="2009-03-20 16:31:15 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-03-20 16:31:15 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17230418"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Modell-2008" MODIFIED="2011-05-12 16:50:37 +0100" MODIFIED_BY="[Empty name]" NAME="Modell 2008" TYPE="JOURNAL_ARTICLE">
<AU>Modell B, Darlison M</AU>
<TI>Global epidemiology of haemoglobin disorders and derived service indicators</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2008</YR>
<VL>86</VL>
<NO>6</NO>
<PG>480-7</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:50:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Mortensen-2002" NAME="Mortensen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN et al</AU>
<TI>Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<NO>9</NO>
<PG>1059-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mousa-2010" MODIFIED="2011-05-12 16:51:02 +0100" MODIFIED_BY="[Empty name]" NAME="Mousa 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mousa SA, Qari MH</AU>
<TI>Diagnosis and management of sickle cell disorders</TI>
<SO>Methods in Molecular Biology</SO>
<YR>2010</YR>
<VL>663</VL>
<PG>291-307</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:51:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Neumayr-2003" NAME="Neumayr 2003" TYPE="JOURNAL_ARTICLE">
<AU>Neumayr L, Lennette E, Kelly D, Earles A, Embury S, Groncy P, et al</AU>
<TI>Mycoplasma disease and acute chest syndrome in sickle cell disease</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<NO>1 Pt 1</NO>
<PG>87-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-2002" NAME="NIH 2002" TYPE="BOOK">
<AU>National Heart, Lung, and Blood Institute, Division of Blood Disease and Resources</AU>
<SO>The Management of Sickle Cell Disease</SO>
<YR>2002</YR>
<EN>4th</EN>
<PB>National Institutes of Health</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Orkin-2010" MODIFIED="2011-05-12 16:51:19 +0100" MODIFIED_BY="[Empty name]" NAME="Orkin 2010" TYPE="JOURNAL_ARTICLE">
<AU>Orkin SH, Higgs DR</AU>
<TI>Medicine. Sickle cell disease at 100 years</TI>
<SO>Science</SO>
<YR>2010</YR>
<VL>329</VL>
<NO>5989</NO>
<PG>291-2</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:51:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Overturf-1999" NAME="Overturf 1999" NOTES="&lt;p&gt;no issue number&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Overturf GD</AU>
<TI>Infections and immunizations of children with sickle cell disease</TI>
<SO>Advances in Pediatric Infectious Diseases</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>191-218</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overturf-2000" NAME="Overturf 2000" TYPE="JOURNAL_ARTICLE">
<AU>Overturf GD</AU>
<TI>American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>106</VL>
<NO>2 Pt 1</NO>
<PG>367-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paradisi-2000" NAME="Paradisi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Paradisi F, Corti G</AU>
<TI>Antibiotic resistance in community-acquired pulmonary pathogens</TI>
<SO>Seminars in Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>1</NO>
<PG>33-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1949" NAME="Pauling 1949" TYPE="JOURNAL_ARTICLE">
<AU>Pauling L, Itano HA, Singer SJ, Wells IC</AU>
<TI>Sickle cell anemia, a molecular disease</TI>
<SO>Science</SO>
<YR>1949</YR>
<VL>110</VL>
<NO>2865</NO>
<PG>543-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pelton-2005" NAME="Pelton 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pelton SI, Hammerschlag MR</AU>
<TI>Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children</TI>
<SO>Clinical Pediatrics</SO>
<YR>2005</YR>
<VL>44</VL>
<NO>1</NO>
<PG>1-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petri-2001" MODIFIED="2012-07-20 13:46:07 +0100" MODIFIED_BY="[Empty name]" NAME="Petri 2001" TYPE="BOOK_SECTION">
<AU>Petri, Jr WA</AU>
<TI>Penicillins, cephalosporins, and other &#946;-lactam antibiotics</TI>
<SO>Goodman &amp; Gilman's. The Pharmacological Basis of Therapeutics</SO>
<YR>2001</YR>
<PG>1189-218</PG>
<EN>10</EN>
<ED>Hardman JG, Limbird LE</ED>
<PB>McGraw Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pimentel-2003" NAME="Pimentel 2003" TYPE="JOURNAL_ARTICLE">
<AU>Pimentel L, McPherson SJ</AU>
<TI>Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management</TI>
<SO>Emergency Medicine Clinics of North America</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>2</NO>
<PG>395-420</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plouffe-2004" NAME="Plouffe 2004" TYPE="JOURNAL_ARTICLE">
<AU>Plouffe Jr JF, Martin DR</AU>
<TI>Re-evaluation of the therapy of severe pneumonia caused by Streptococcus pneumoniae</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>4</NO>
<PG>963&#8211;74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prabhakar-2010" MODIFIED="2011-05-12 16:51:46 +0100" MODIFIED_BY="[Empty name]" NAME="Prabhakar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Prabhakar H, Haywood C Jr, Molokie R</AU>
<TI>Sickle cell disease in the United States: looking back and forward at 100 years of progress in management and survival</TI>
<SO>American Journal of Hematology</SO>
<YR>2010</YR>
<VL>85</VL>
<NO>5</NO>
<PG>346-53</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:51:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ramakrishnan-2010" MODIFIED="2011-05-10 00:16:36 +0100" MODIFIED_BY="[Empty name]" NAME="Ramakrishnan 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ramakrishnan M, Moisi JC, Klugman KP, Iglesias JM, Grant LR, Mpoudi-Etame M et al</AU>
<TI>Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis</TI>
<SO>The Lancet Infectious Diseases</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>5</NO>
<PG>329-37</PG>
<IDENTIFIERS MODIFIED="2011-05-10 00:16:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rees-2010" MODIFIED="2011-05-12 16:52:00 +0100" MODIFIED_BY="[Empty name]" NAME="Rees 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rees DC, Williams TN, Gladwin MT</AU>
<TI>Sickle-cell disease</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9757</NO>
<PG>2018-31</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:52:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-05-05 20:52:42 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Copenhagen: The Nordic Cochrane Centre</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandora-2005" NAME="Sandora 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sandora TJ, Harper MB</AU>
<TI>Pneumonia in hospitalized children</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>4</NO>
<PG>1059-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saunthararajah-2005" NAME="Saunthararajah 2005" TYPE="BOOK_SECTION">
<AU>Saunthararajah Y, Vichinsky EP, Embury SH</AU>
<TI>Sickle cell disease</TI>
<SO>Hematology: Basic Principles and Practice</SO>
<YR>2005</YR>
<PB>Churchill Livingstone</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Segreti-2005" NAME="Segreti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Segreti J, House HR, Siegel RE</AU>
<TI>Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting</TI>
<SO>American Journal of Medicine</SO>
<YR>2005</YR>
<VL>118</VL>
<NO>Suppl 7A</NO>
<PG>21S-8S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selim-2010" MODIFIED="2012-09-06 13:20:37 +0100" MODIFIED_BY="[Empty name]" NAME="Selim 2010" TYPE="COCHRANE_PROTOCOL">
<AU>Selim AG, Balalis G, Bhaskar B, van Driel ML</AU>
<TI>Antibiotics for ventilator-associated pneumonia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-09-06 12:55:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-09-06 12:55:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004267.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-2010" MODIFIED="2011-05-12 16:52:19 +0100" MODIFIED_BY="[Empty name]" NAME="Serjeant 2010" TYPE="JOURNAL_ARTICLE">
<AU>Serjeant GR</AU>
<TI>One hundred years of sickle cell disease</TI>
<SO>British Journal of Haematology</SO>
<YR>2010</YR>
<VL>151</VL>
<NO>5</NO>
<PG>425-9</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:52:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Siddiqui-2003" NAME="Siddiqui 2003" TYPE="JOURNAL_ARTICLE">
<AU>Siddiqui AK , Ahmed S</AU>
<TI>Pulmonary manifestations of sickle cell disease</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2003</YR>
<VL>79</VL>
<NO>933</NO>
<PG>384-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinberg-2009" MODIFIED="2011-05-12 16:34:22 +0100" MODIFIED_BY="[Empty name]" NAME="Steinberg 2009" TYPE="JOURNAL_ARTICLE">
<AU>Steinberg MH</AU>
<TI>Genetic etiologies for phenotypic diversity in sickle cell anemia</TI>
<SO>TheScientificWorldJournal</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>46-67</PG>
<IDENTIFIERS MODIFIED="2011-05-12 16:34:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="19151898"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stuart-2001" NAME="Stuart 2001" TYPE="JOURNAL_ARTICLE">
<AU>Stuart MJ, Setty BN</AU>
<TI>Acute chest syndrome of sickle cell disease: new light on an old problem</TI>
<SO>Current Opinion Hematology</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>2</NO>
<PG>111-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stuart-2004" MODIFIED="2009-03-23 16:06:27 +0000" MODIFIED_BY="[Empty name]" NAME="Stuart 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stuart MJ, Nagel RL</AU>
<TI>Sickle-cell disease</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364(9442)</VL>
<PG>1343-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2004" NAME="Tan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tan JS</AU>
<TI>Nonresponses and treatment failures with conventional empiric regimens in patients with community-acquired pneumonia</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>4</NO>
<PG>883-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vichinsky-1997" NAME="Vichinsky 1997" TYPE="JOURNAL_ARTICLE">
<AU>Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B</AU>
<TI>Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>5</NO>
<PG>1787-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vichinsky-2000" NAME="Vichinsky 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al</AU>
<TI>Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>25</NO>
<PG>1855-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vij-2010" MODIFIED="2011-05-09 23:43:38 +0100" MODIFIED_BY="[Empty name]" NAME="Vij 2010" TYPE="JOURNAL_ARTICLE">
<AU>Vij R, Machado RF</AU>
<TI>Pulmonary complications of hemoglobinopathies</TI>
<SO>Chest</SO>
<YR>2010</YR>
<VL>138</VL>
<NO>4</NO>
<PG>973-83</PG>
<IDENTIFIERS MODIFIED="2011-05-09 23:43:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Waghorn-2001" NAME="Waghorn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Waghorn DJ</AU>
<TI>Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed</TI>
<SO>Journal Clinical of Patholology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>3</NO>
<PG>214-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waterer-2005" NAME="Waterer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Waterer GW, Wunderink RG</AU>
<TI>Genetic susceptibility to pneumonia</TI>
<SO>Clinics in chest medicine</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>1</NO>
<PG>29-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weatherall-2006" MODIFIED="2009-03-23 16:04:06 +0000" MODIFIED_BY="[Empty name]" NAME="Weatherall 2006" TYPE="BOOK_SECTION">
<AU>Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P</AU>
<TI>Inherited Disorders of Hemoglobin</TI>
<SO>Disease Control Priorities in Developing Countries</SO>
<YR>2006</YR>
<VL>2nd edition</VL>
<PB>The World Bank and Oxford University Press</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2009-06-15 12:54:43 +0100" MODIFIED_BY="Nikki Jahnke" NAME="WHO 2002" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Evidence base for the community management of pneumonia</TI>
<SO>http://www.who.int/child-adolescent-health/New_Publications/CHILD_HEALTH/WHO_FCH_CAH_02.23.pdf</SO>
<YR>(accessed 29 December 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2004" NAME="WHO 2004" TYPE="OTHER">
<AU>WHO 2004</AU>
<TI>Pneumococcal vaccines</TI>
<SO>http://www.who.int/vaccines/en/pneumococcus.shtml</SO>
<YR>(accessed 04 February 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" MODIFIED="2009-06-15 12:54:55 +0100" MODIFIED_BY="Nikki Jahnke" NAME="WHO 2005" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Monogenic diseases</TI>
<SO>http://www.who.int/genomics/public/geneticdiseases/en/index2.html#SCA</SO>
<YR>(accessed 29 December 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2009-04-15 13:04:03 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood KC, Hsu LL, Gladwin MT</AU>
<TI>Sickle cell disease vasculopathy: a state of nitric oxide resistance</TI>
<SO>Free Radical Biology and Medicine</SO>
<YR>2008</YR>
<VL>44</VL>
<NO>8</NO>
<PG>1506-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zago-1983" NAME="Zago 1983" TYPE="JOURNAL_ARTICLE">
<AU>Zago MA, Bottura C</AU>
<TI>Splenic function in sickle-cell diseases</TI>
<SO>Clinical Science (London, England : 1979)</SO>
<YR>1983</YR>
<VL>65</VL>
<NO>3</NO>
<PG>297-302</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-09-23 12:31:45 +0100" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2006" MODIFIED="2011-05-12 17:17:33 +0100" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2006" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Conterno L</AU>
<TI>Antibiotics for treating community acquired pneumonia in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-05-12 17:17:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2011-05-12 17:17:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005598.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2012" MODIFIED="2016-09-23 12:31:45 +0100" MODIFIED_BY="Tracey Remmington" NAME="Martí-Carvajal 2012" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Conterno LO</AU>
<TI>Antibiotics for treating community acquired pneumonia in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2016-09-23 12:31:45 +0100" MODIFIED_BY="Tracey Remmington"><IDENTIFIER MODIFIED="2016-09-23 12:31:45 +0100" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD005598.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-09-23 12:05:01 +0100" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Lederman-2014" MODIFIED="2016-09-23 12:05:01 +0100" MODIFIED_BY="Tracey Remmington" NAME="Lederman 2014" TYPE="JOURNAL_ARTICLE">
<AU>Lederman HM, Connolly MA, Kalpatthi R, Ware RE, Wang WC, Luchtman-Jones L, et al</AU>
<TI>Immunologic effects of hydroxyurea in sickle cell anemia</TI>
<SO>Pediatrics</SO>
<YR>2014</YR>
<VL>134</VL>
<NO>4</NO>
<PG>686-95</PG>
<IDENTIFIERS MODIFIED="2016-09-23 12:05:00 +0100" MODIFIED_BY="Tracey Remmington"><IDENTIFIER TYPE="CENTRAL" VALUE="1053679"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000000943"/><IDENTIFIER TYPE="PUBMED" VALUE="25180279"/></IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-05 16:36:24 +0000" MODIFIED_BY="Tracey Remmington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-05 16:36:24 +0000" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-05 16:28:48 +0000" MODIFIED_BY="Tracey Remmington"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2012-04-27 17:31:06 +0100" MODIFIED_BY="[Empty name]"/>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-11-09 11:26:49 +0000" MODIFIED_BY="Tracey Remmington">
<APPENDIX ID="APP-01" MODIFIED="2016-11-09 11:26:49 +0000" MODIFIED_BY="Tracey Remmington" NO="1">
<TITLE MODIFIED="2011-04-03 15:04:40 +0100" MODIFIED_BY="[Empty name]">Glossary</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-09 11:26:49 +0000" MODIFIED_BY="Tracey Remmington">
<TABLE COLS="3" ROWS="10">
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Term</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Definition</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Source</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Anemia, Sickle cell</P>
</TD>
<TD VALIGN="TOP">
<P>A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic</P>
<P>involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Anti-bacterial agents</P>
</TD>
<TD VALIGN="TOP">
<P>Substances that reduce the growth or reproduction of bacteria</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Community-acquired Infections</P>
</TD>
<TD VALIGN="TOP">
<P>Any infection acquired in the community, that is, contrasted with those acquired in a health care facility</P>
<P>(CROSS INFECTION). An infection would be classified as community-acquired if the patient had not recently been in a health care facility or been in contact with someone who had been recently in a health care facility.</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Hemoglobin, sickle</P>
</TD>
<TD VALIGN="TOP">
<P>An abnormal hemoglobin resulting from the substitution of valine for glutamic acid at position 6 of the beta chain of the globin moiety. The heterozygous state results in sickle cell trait, the homozygous in sickle cell anemia.</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Hemoglobin SC Disease</P>
</TD>
<TD VALIGN="TOP">
<P>One of the sickle cell disorders characterized by the presence of both hemoglobin S and hemoglobin C. It is similar to, but less severe than sickle cell anemia.</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pneumonia</P>
</TD>
<TD VALIGN="TOP">
<P>Inflammation of any part, segment or lobe, of the lung parenchyma.</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pneumonia, pneumococcal</P>
</TD>
<TD VALIGN="TOP">
<P>A febrile disease caused by Streptococcus pneumoniae.</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sickle cell trait</P>
</TD>
<TD VALIGN="TOP">
<P>The condition of being heterozygous for hemoglobin S.</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vaccines</P>
</TD>
<TD VALIGN="TOP">
<P>Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa, or rickettsiae), antigenic proteins derived from them, or synthetic constructs, administered for the prevention, amelioration, or treatment of infectious and other diseases.</P>
</TD>
<TD VALIGN="TOP">
<P> MeSH (Medical Subject Headings). National Library of Medicine (<A HREF="http://www.ncbi.nlm.nih.gov/mesh">www.ncbi.nlm.nih.gov/mesh</A>).</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-10-20 15:36:43 +0100" MODIFIED_BY="Arturo J Martí-Carvajal" NO="2">
<TITLE MODIFIED="2016-10-20 15:36:43 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">Search strategy LILACS - (via www.bireme.br) 1982 to 01/09/2016</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-20 15:33:32 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search Strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>LILACS </P>
<P>Search carried out: 01/09/2016</P>
<P>Searched for all years using advanced search form:</P>
<P>
<A HREF="http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;base=LILACS&#9001;=i&amp;form=A">http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=A</A>
</P>
<P>
<B>LINE 1</B>
</P>
<P/>
<P>(sickle or anemia falciforme anemia de celulas falciformes or drepanocitosis or "SICKLE" or "SICKLE CELL HEMOGLOBIN C DISEASE" or "SICKLE CELL HEMOGLOBIN C DISEASE/" or "SICKLE CELL HEMOGLOBIN C DISEASE/BL" or "SICKLE CELL HEMOGLOBIN C DISEASE/CO" or "SICKLE CELL HEMOGLOBIN C DISEASE/DI" or "SICKLE CELL HEMOGLOBIN C DISEASE/DT" or "SICKLE CELL HEMOGLOBIN C DISEASE/EP" or "SICKLE CELL HEMOGLOBIN C DISEASE/ET" or "SICKLE CELL HEMOGLOBIN C DISEASE/GE" or "SICKLE CELL HEMOGLOBIN C DISEASE/MI" or "SICKLE CELL HEMOGLOBIN C DISEASE/PA" or "SICKLE CELL HEMOGLOBIN C DISEASE/PC" or "SICKLE CELL HEMOGLOBIN C DISEASE/PP" or "SICKLE CELL HEMOGLOBIN C DISEASE/TH" or "SICKLE CELL HEMOGLOBIN C DISEASE/UR" or "SICKLECELL" or "ANEMIA, SICKLE CELL" or "ANEMIA, SICKLE CELL/" or "ANEMIA, SICKLE CELL/AN" or "ANEMIA, SICKLE CELL/BL" or "ANEMIA, SICKLE CELL/CL" or "ANEMIA, SICKLE CELL/CN" or "ANEMIA, SICKLE CELL/CO" or "ANEMIA, SICKLE CELL/DI" or "ANEMIA, SICKLE CELL/DT" or "ANEMIA, SICKLE CELL/EH" or "ANEMIA, SICKLE CELL/EN" or "ANEMIA, SICKLE CELL/EP" or "ANEMIA, SICKLE CELL/ET" or "ANEMIA, SICKLE CELL/GE" or "ANEMIA, SICKLE CELL/HI" or "ANEMIA, SICKLE CELL/IM" or "ANEMIA, SICKLE CELL/ME" or "ANEMIA, SICKLE CELL/MI" or "ANEMIA, SICKLE CELL/MO" or "ANEMIA, SICKLE CELL/NU" or "ANEMIA, SICKLE CELL/PA" or "ANEMIA, SICKLE CELL/PC" or "ANEMIA, SICKLE CELL/PP" or "ANEMIA, SICKLE CELL/PX" or "ANEMIA, SICKLE CELL/RI" or "ANEMIA, SICKLE CELL/SU" or "ANEMIA, SICKLE CELL/TH" or "ANEMIA, SICKLE CELL/UR" or "ANEMIA, SICKLE CELL/US" or "HEMOGLOBIN S DISEASE" or "HEMOGLOBIN S DISEASE/" or "HEMOGLOBIN S DISEASE/AN" or "HEMOGLOBIN S DISEASE/BL" or "HEMOGLOBIN S DISEASE/CL" or "HEMOGLOBIN S DISEASE/CN" or "HEMOGLOBIN S DISEASE/CO" or "HEMOGLOBIN S DISEASE/DI" or "HEMOGLOBIN S DISEASE/DT" or "HEMOGLOBIN S DISEASE/EH" or "HEMOGLOBIN S DISEASE/EN" or "HEMOGLOBIN S DISEASE/EP" or "HEMOGLOBIN S DISEASE/ET" or "HEMOGLOBIN S DISEASE/GE" or "HEMOGLOBIN S DISEASE/HI" or "HEMOGLOBIN S DISEASE/IM" or "HEMOGLOBIN S DISEASE/ME" or "HEMOGLOBIN S DISEASE/MI" or "HEMOGLOBIN S DISEASE/MO" or "HEMOGLOBIN S DISEASE/NU" or "HEMOGLOBIN S DISEASE/PA" or "HEMOGLOBIN S DISEASE/PC" or "HEMOGLOBIN S DISEASE/PP" or "HEMOGLOBIN S DISEASE/PX" or "HEMOGLOBIN S DISEASE/RI" or "HEMOGLOBIN S DISEASE/SU" or "HEMOGLOBIN S DISEASE/TH" or "HEMOGLOBIN S DISEASE/UR" or "HEMOGLOBIN S DISEASE/US" or "HEMOGLOBIN SC DISEASE" or "HEMOGLOBIN SC DISEASE/" or "HEMOGLOBIN SC DISEASE/BL" or "HEMOGLOBIN SC DISEASE/CO" or "HEMOGLOBIN SC DISEASE/DI" or "HEMOGLOBIN SC DISEASE/DT" or "HEMOGLOBIN SC DISEASE/EP" or "HEMOGLOBIN SC DISEASE/ET" or "HEMOGLOBIN SC DISEASE/GE" or "HEMOGLOBIN SC DISEASE/MI" or "HEMOGLOBIN SC DISEASE/PA" or "HEMOGLOBIN SC DISEASE/PC" or "HEMOGLOBIN SC DISEASE/PP" or "HEMOGLOBIN SC DISEASE/TH" or "HEMOGLOBIN SC DISEASE/UR")</P>
<P/>
<P>
<B>LINE 2</B>
</P>
<P/>
<P>(Neumonia or pneumonia or low tract infection) or "NEUMONIA" or "NEUMONIAADQUIRIDA"</P>
<P>Search results: 19 references</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-10-20 15:43:30 +0100" MODIFIED_BY="Arturo J Martí-Carvajal" NO="3">
<TITLE MODIFIED="2016-10-20 15:43:30 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">African Index Medicus (up to 20/10/2016)</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-20 15:39:03 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>African Index Medicus<BR/>Search carried out: 01/09/2016<BR/>Searched for all years using advanced search form:<BR/>http://indexmedicus.afro.who.int/cgi-bin/wxis.exe/iah/</P>
<P>
<B>LINE 1</B>
</P>
<P>(sickle or anemia falciforme anemia de celulas falciformes or drepanocitosis or "SICKLE" or "SICKLE CELL HEMOGLOBIN C DISEASE" or "SICKLE CELL HEMOGLOBIN C DISEASE/" or "SICKLE CELL HEMOGLOBIN C DISEASE/BL" or "SICKLE CELL HEMOGLOBIN C DISEASE/CO" or "SICKLE CELL HEMOGLOBIN C DISEASE/DI" or "SICKLE CELL HEMOGLOBIN C DISEASE/DT" or "SICKLE CELL HEMOGLOBIN C DISEASE/EP" or "SICKLE CELL HEMOGLOBIN C DISEASE/ET" or "SICKLE CELL HEMOGLOBIN C DISEASE/GE" or "SICKLE CELL HEMOGLOBIN C DISEASE/MI" or "SICKLE CELL HEMOGLOBIN C DISEASE/PA" or "SICKLE CELL HEMOGLOBIN C DISEASE/PC" or "SICKLE CELL HEMOGLOBIN C DISEASE/PP" or "SICKLE CELL HEMOGLOBIN C DISEASE/TH" or "SICKLE CELL HEMOGLOBIN C DISEASE/UR" or "SICKLECELL" or "ANEMIA, SICKLE CELL" or "ANEMIA, SICKLE CELL/" or "ANEMIA, SICKLE CELL/AN" or "ANEMIA, SICKLE CELL/BL" or "ANEMIA, SICKLE CELL/CL" or "ANEMIA, SICKLE CELL/CN" or "ANEMIA, SICKLE CELL/CO" or "ANEMIA, SICKLE CELL/DI" or "ANEMIA, SICKLE CELL/DT" or "ANEMIA, SICKLE CELL/EH" or "ANEMIA, SICKLE CELL/EN" or "ANEMIA, SICKLE CELL/EP" or "ANEMIA, SICKLE CELL/ET" or "ANEMIA, SICKLE CELL/GE" or "ANEMIA, SICKLE CELL/HI" or "ANEMIA, SICKLE CELL/IM" or "ANEMIA, SICKLE CELL/ME" or "ANEMIA, SICKLE CELL/MI" or "ANEMIA, SICKLE CELL/MO" or "ANEMIA, SICKLE CELL/NU" or "ANEMIA, SICKLE CELL/PA" or "ANEMIA, SICKLE CELL/PC" or "ANEMIA, SICKLE CELL/PP" or "ANEMIA, SICKLE CELL/PX" or "ANEMIA, SICKLE CELL/RI" or "ANEMIA, SICKLE CELL/SU" or "ANEMIA, SICKLE CELL/TH" or "ANEMIA, SICKLE CELL/UR" or "ANEMIA, SICKLE CELL/US" or "HEMOGLOBIN S DISEASE" or "HEMOGLOBIN S DISEASE/" or "HEMOGLOBIN S DISEASE/AN" or "HEMOGLOBIN S DISEASE/BL" or "HEMOGLOBIN S DISEASE/CL" or "HEMOGLOBIN S DISEASE/CN" or "HEMOGLOBIN S DISEASE/CO" or "HEMOGLOBIN S DISEASE/DI" or "HEMOGLOBIN S DISEASE/DT" or "HEMOGLOBIN S DISEASE/EH" or "HEMOGLOBIN S DISEASE/EN" or "HEMOGLOBIN S DISEASE/EP" or "HEMOGLOBIN S DISEASE/ET" or "HEMOGLOBIN S DISEASE/GE" or "HEMOGLOBIN S DISEASE/HI" or "HEMOGLOBIN S DISEASE/IM" or "HEMOGLOBIN S DISEASE/ME" or "HEMOGLOBIN S DISEASE/MI" or "HEMOGLOBIN S DISEASE/MO" or "HEMOGLOBIN S DISEASE/NU" or "HEMOGLOBIN S DISEASE/PA" or "HEMOGLOBIN S DISEASE/PC" or "HEMOGLOBIN S DISEASE/PP" or "HEMOGLOBIN S DISEASE/PX" or "HEMOGLOBIN S DISEASE/RI" or "HEMOGLOBIN S DISEASE/SU" or "HEMOGLOBIN S DISEASE/TH" or "HEMOGLOBIN S DISEASE/UR" or "HEMOGLOBIN S DISEASE/US" or "HEMOGLOBIN SC DISEASE" or "HEMOGLOBIN SC DISEASE/" or "HEMOGLOBIN SC DISEASE/BL" or "HEMOGLOBIN SC DISEASE/CO" or "HEMOGLOBIN SC DISEASE/DI" or "HEMOGLOBIN SC DISEASE/DT" or "HEMOGLOBIN SC DISEASE/EP" or "HEMOGLOBIN SC DISEASE/ET" or "HEMOGLOBIN SC DISEASE/GE" or "HEMOGLOBIN SC DISEASE/MI" or "HEMOGLOBIN SC DISEASE/PA" or "HEMOGLOBIN SC DISEASE/PC" or "HEMOGLOBIN SC DISEASE/PP" or "HEMOGLOBIN SC DISEASE/TH" or "HEMOGLOBIN SC DISEASE/UR")</P>
<P>
<B>LINE 2</B>
</P>
<P>(Neumonia or pneumonia or low tract infection) or "NEUMONIA" or "NEUMONIAADQUIRIDA"</P>
<P>Search results: 0 references</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-10-20 16:13:18 +0100" MODIFIED_BY="Arturo J Martí-Carvajal" NO="4">
<TITLE MODIFIED="2016-10-20 15:43:00 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">World Health Organization. International Clinical Trials. Registry Platform Search Portal (20/10/2016)</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-20 16:13:18 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>Search carried out: 01/09/2016<BR/>Sickle AND pneumonia AND antibiotic<BR/>Results: 0 references.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-10-20 16:13:59 +0100" MODIFIED_BY="Arturo J Martí-Carvajal" NO="5">
<TITLE MODIFIED="2016-10-20 16:13:59 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">ClinicalTrials.gov (20/10/2016)</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-20 16:12:39 +0100" MODIFIED_BY="Arturo J Martí-Carvajal">
<P>Search carried out: 01/09/2016<BR/>Sickle AND pneumonia<BR/>Searched for all years using advanced search form:<BR/>https://clinicaltrials.gov/ct2/results?term=%22sickle%22+AND+%22pneumonia%22</P>
<P>Results: 16 references.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>